CONFERENCE UPDATE View All
NEWS & PERSPECTIVE View All
Features View All

Exploring the underlying causes and patient experience of myasthenia gravis

Despite emerging insights into the pathogenesis of autoimmune diseases, systemic board-spectrum immunosuppression remains as the backbone of treatment for these diseases.1 However, as immunosuppression is associated with numerous long-term side effects, there is a high unmet need for treatments that

28 Jun 2021
thumb

Professor James F. Howard, Jr.

Professor of Neurology,
Medicine and Allied Health,
The University of North Carolina at Chapel Hill, United States

thumb

Dr. Saiju Jacob

Consultant Neurologist and Neuroimmunologist,
Clinical Service Lead for Neurology,
University Hospitals Birmingham, United Kingdom

thumb

Ms. Nancy Law

Former Chief Executive Officer and current Board Chair,
Myasthenia Gravis Foundation of America, Colorado, United States